Centiva Capital’s Cullinan Oncology CGEM Stock Holding History

Centiva Capital’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,497	Closed	-$128K	–	1664
2023 Q1	$128K	Buy	+12,497	New	+$138K	﹤0.01%	1313

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

AIG

American International Group New York $2.93M AUM 12.08% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Centiva Capital's CGEM Position: Q2 2023 in Review

Centiva Capital sold out of Cullinan Oncology (CGEM) in Q2 2023, closing a stake of 12,497 shares — an estimated $128K sold.

Centiva Capital first reported a position in CGEM in Q1 2023 and held it in 1 quarter. The position peaked at $128K in Q1 2023. 106 funds tracked by Wall St. Rank hold CGEM as of Q2 2023.

Centiva Capital reported no remaining Cullinan Oncology position as of Q2 2023 after selling out during the quarter.
Centiva Capital sold 12,497 Cullinan Oncology shares in Q2 2023, an estimated $128K.
Centiva Capital first reported a position in Cullinan Oncology in Q1 2023 and held it in 1 quarter.
Centiva Capital's Cullinan Oncology position peaked at $128K in Q1 2023.
106 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.